Area(s) of expertise: Senior VP, Quintiles Outcome
Summary of expertise:
Dr. Nancy Dreyer is Global Chief of Scientific Affairs and Senior Vice President at Quintiles Real-World & Late Phase Research. She leads a team of researchers who design, conduct, and interpret observational research on comparative effectiveness, safety and quality improvement programs.
In 2009, Dr. Dreyer joined the Steering Committee for the European Medicines Agency’s PROTECT Project for the Innovative Medicines Initiative. In 2007, she was recognized by the trade journal, Pharmavoice as one of the 100 most inspiring people in the pharmaceutical and life sciences industry.
Dr. Dreyer has more than 25 years of experience in epidemiologic research. She trained at the University of North Carolina in Chapel Hill, earning a masters degree and doctorate in Epidemiology. Dr. Dreyer was CEO of Epidemiology Resources, Inc., a job she held from the company’s inception through its acquisition 20 years later by UnitedHealth Group. In that role, she launched and published the peer‑reviewed journal, Epidemiology, for its first 10 years, and led the New England Epidemiology Institute, a summer program that trained more than 5,000 scientists through collaboration with international medical schools and schools of public health. Dr. Dreyer is an Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill, a Fellow and Board Member of the International Society of Pharmacoepidemiology, and a director of the Drug Information Association. She is also a member of the Interim Steering Committee for the FDA’s new medical device epidemiology network (MDEpiNet), and is co-lead investigator for a study on developing new methodologies for pharmacovigilance. In 2013, Dr. Dreyer was appointed as a member of the Academic Consulting Committee at the Center of Postmarketing Safety Evaluation at Peking University Health Science Center in China.
Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality. January 2013.
Velentgas P, Dreyer NA, Wu AW. Outcome definition and measurement. In Velentgas P, Dreyer, NA, Nourjah P et al., eds. Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide. Rockville, MD: Agency for Healthcare Research and Quality. 2013: Chapter 6, pp. 71-92.
Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User’s Guide. Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No.
HHSA29020050035I TO1. AHRQ Publication No. 07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality. 2nd Edition, September, 2010. Also available in Korean through the Korean National Evidence-based Healthcare Collaborating Agency, published December 31, 2010. and in Chinese, published in December, 2012. Third edition, in press
Dreyer NA, Toovey S, Oner AF, Bamgboye E, Dogan N, Zaman M, Gasimov V, Adisasmito W, Coker R, Chan PKS, Lee N, Tsang O, Hanshaoworakul W, Phommasack B, Touch S, Swenson A, Reddy D: Investigating outbreaks of novel infectious disease: an international case study. Journal of Clinical Studies 2013; 5(2):52-53.
Adisasmito w, Aisyah DN, Aditama TY, Kusriastuti R, Trihono, Suwandono A, Sampurno OD, Prasenohadi, Sapada NA, Mamahit MJN, Swenson A, Dreyer NA, Coker R. Human influenza A H5N1 in Indonesia health care service-associated delays in treatment initiation, BMC Public Health 2013; 13:571-577.
Dreyer NA. Using observational studies for comparative effectiveness: Finding quality with GRACE. Journal of Comparative Effectiveness Research 2013; 2(5):413-418.
Dreyer NA, Dixon JB, Okerson T, Finkelstein EA, Globe D. Prevalence of Comorbidities and Baseline Characteristics of LAP-BAND AP® Subjects in the Helping Evaluate Reduction in Obesity (HERO) Study. PLOS One 2013; 8(11): e78971. doi:10.1371/journal.pone.0078971
Dreyer NA, Velentgas P. Registries. In Pharmacoepidemiology, Strom B, Kimmel S, Hennessy S, Eds. Fifth edition, John Wiley & Sons Ltd., 2012.
Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand, SL. Prospective observational studies to assess comparative effectiveness: ISPOR good research practices task force report. Value in Health 2012;15(2):217-30.
Gliklich RE, Leavy MB, Velentgas P, Dreyer NA, Tunis SR, Mohr P, Messner DA, Moloney RM, Karkare Su, Dubois RW, Graff JS: Incorporating Stakeholder Perspectives in Developing a Translation Table Framework for Comparative Effectiveness Research. Journal of Comparative Effectiveness Research 2012; 1(3):281-292.
REGISTER Group (Campbell B, Patrick H, Dreyer NA, Grilli R, Franklin GM, Lee Robin SH, Maddern G, Tunis S, Lyratzopoulos). International collaboration in the use of registries for new devices and procedures. British Journal of Surgery 2012; 99: 744–745.Chan PKS, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasmiov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bangboye E, Swenson A, Toovey S, Dreyer N: Determinants of Antiviral Effectiveness in H5N1 Avian Influenza. Journal of Infectious Disease 2012; 206: 1359-66.
•Clinical presentation of avian influenza
•The GRACE Checklist for Observational Studies of Comparative Effectiveness: Validation Study
•Using real-world information to inform decision making
Dr. Dreyer earned a masters degree and doctorate in Epidemiology from the University of North Carolina in Chapel Hill.
Areas of expertise:
•The value of bringing population science to clinical research
•Current and future uses of registries to evaluate patient outcomes
•Advancing good practice guidance on observational methods for effectiveness and safety
No comments have been made.